Sjödahl et al. reported two different genomic circuits operative in urothelial carcinomas: one defined by high FGFR3 and CCND1 expression, low CDKN2A expression, often associated with CDKN2A loss and the other one defined by E2F3 amplifications and overexpression, RB1 deletions and low expression and high CDKN2A/p16 expression27. The gene discussed is CDKN2A; the disease is urothelial carcinoma.